SNC-115

N/A

Report date: 2025/11/05 15:24:28

Base Information

Drug NameSNC-115
Drug Alias NameSNC115SNC-115
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionDelta-like protein 3 modulatorsT lymphocyte replacements
TargetsDelta-like protein 3
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Simnova Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A